Fig. 3: Anti-tumour efficacies of AECM@PC7A in multiple tumour models.
From: Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapy
a Representative histogram of MHC-I presentation on B16-OVA cells post IFN-γ treatment. b–e C57BL/6 mice inoculated with 1.5 × 105 B16-OVA cells were vaccinated at the dose of 300 μg per shot, tumour growth curves (b) and mice survival (c) were shown (n = 10 mice/group). Representative images (d) and quantification (e) of IFN-γ+ ELISPOT responses in splenocytes upon re-stimulation with the OVA257-264 peptide (n = 5 mice/group). f Representative histogram of MHC-I presentation on MC38 cells post IFN-γ treatment. g–i C57BL/6 mice inoculated with 2.5 × 105 MC38 cells were vaccinated at the dose of 100 μg per shot, tumour growth curves (g) and mice survival (h) were shown (n = 10 mice/group). The IFN-γ secretion by CD8+ T-cells in splenocytes upon re-stimulation with Adpgk and Rpl18 neo-peptides were determined by intracellular staining (ICS) (i, n = 5 mice/group). j Representative histogram of MHC-I presentation on CT26 cells post IFN-γ treatment. k–m BALB/c mice inoculated with 1.5 × 105 CT26 cells were vaccinated at the dose of 300 μg per shot, tumour growth curves (k) and mice survival (l) were shown (n = 5 mice/group). The IFN-γ secretion by CD8+ T-cells in splenocytes upon re-stimulation with AH1 or M19 neo-peptides was determined by ICS (m, n = 5 mice/group). n C57BL/6 mice inoculated with 1.5 × 105 B16-OVA cells were treated three doses of PC7A vaccines that incorporated 300 μg AECM or cell lysates from IFN-γ treated B16-OVA cells, tumour growth curves were shown (n = 5 mice/group). o, C57BL/6 mice inoculated with 1.5×105 B16-F10 cells were treated three doses of PC7A vaccines that incorporated 500 µg AECM/CM of B16-F10, or 0.5 µg/2.5 µg peptide pool (with equivalent ratio of Gp10021–41, Trp1214–237, Trp2173–196, B16-M27, B16-M33), tumour growth curves were shown (n = 5 mice/group). In (b, g, k, n, o) representative data from three independent experiments are presented as means ± s.e.m. Statistical significance was calculated by ordinary one-way ANOVA (b, g, i, k, m, n, o), log-rank test (c, h, l) and Student’s two-sided unpaired t-test (e). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS not significant. Source data are provided as a Source Data file.
